Preclinical model for evaluating human TCRs against chimeric syngeneic tumors

Preclinical model for evaluating human TCRs against chimeric syngeneic tumors

Background The adoptive cell transfer (ACT) of T cell receptor (TCR)-engineered T cells targeting the HLA-A2-restricted epitope NY-ESO-1157-165 (A2/NY) has yielded important clinical responses against several cancers. A variety of approaches are being taken to augment tumor control by ACT including...

Full description

Saved in:
Bibliographic Details
Main Authors: Olivier Michielin, Philippe Guillaume, Melita Irving, Patrick Reichenbach, Vincent Zoete, Elise Gray-Gaillard, Evangelos Stefanidis, Aikaterini Semilietof, Julien Pujol, Alessia D'Esposito
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009504.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/12/e009504.full

Similar Items